“…The PPVs for the endocervical AGUS subcategories demonstrated a marked difference between the "favor neoplasia" designation and either the "unspecified" or "favor reactive" designations in both types of preparations (67% vs. 28% vs. 10% in TPs and 77% vs. 23% vs.4% in CPs). These differences are similar to those reported in other studies of biopsy follow-up results after an AGUS interpretation in CPs, [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] and in one similar study using TPs, 20 and demonstrate that differences in PPVs among endocervical AGUS subcategories are similar in both TPs and CPs. Although the number of cases was small, we found that the AGUS "endometrial" category had a very low PPV in both groups.…”
Section: Discussionsupporting
confidence: 89%
“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] In general, those laboratories that report lower AGUS frequencies have higher PPVs for the detection of a high-grade precursor lesion or carcinoma and for lesions found to have glandular rather than squamous differentiation on follow-up. 6,9,16 In contrast, laboratories with higher AGUS frequencies have shown a high preponderance of either benign processes or high-grade CIN on biopsy follow-up.…”
Section: Discussionmentioning
confidence: 99%
“…AGUS has been a problematic interpretation clinically because biopsy follow-up mostly has shown either a benign reactive process or a squamous precursor lesion (cervical intraepithelial neoplasia [CIN]) rather than a glandular one. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] The ThinPrep Papanicolaou test (TP) (Cytyc Corporation, Boxborough, MA) is a slide preparation method that utilizes liquid fixa-tion of the exfoliated cells. It has been shown to produce well preserved thin-layer slides devoid of the artifacts that may contribute to inaccuracies in the interpretation of conventional smears.…”
“…The PPVs for the endocervical AGUS subcategories demonstrated a marked difference between the "favor neoplasia" designation and either the "unspecified" or "favor reactive" designations in both types of preparations (67% vs. 28% vs. 10% in TPs and 77% vs. 23% vs.4% in CPs). These differences are similar to those reported in other studies of biopsy follow-up results after an AGUS interpretation in CPs, [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] and in one similar study using TPs, 20 and demonstrate that differences in PPVs among endocervical AGUS subcategories are similar in both TPs and CPs. Although the number of cases was small, we found that the AGUS "endometrial" category had a very low PPV in both groups.…”
Section: Discussionsupporting
confidence: 89%
“…[2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] In general, those laboratories that report lower AGUS frequencies have higher PPVs for the detection of a high-grade precursor lesion or carcinoma and for lesions found to have glandular rather than squamous differentiation on follow-up. 6,9,16 In contrast, laboratories with higher AGUS frequencies have shown a high preponderance of either benign processes or high-grade CIN on biopsy follow-up.…”
Section: Discussionmentioning
confidence: 99%
“…AGUS has been a problematic interpretation clinically because biopsy follow-up mostly has shown either a benign reactive process or a squamous precursor lesion (cervical intraepithelial neoplasia [CIN]) rather than a glandular one. [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] The ThinPrep Papanicolaou test (TP) (Cytyc Corporation, Boxborough, MA) is a slide preparation method that utilizes liquid fixa-tion of the exfoliated cells. It has been shown to produce well preserved thin-layer slides devoid of the artifacts that may contribute to inaccuracies in the interpretation of conventional smears.…”
“…Most laboratories report an AGUS rate Ͻ 1%. [3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] The AGUS rate of 0.56% observed among the general patient population in our laboratory was in agreement with the current literature. Few studies have investigated the incidence of atypical endometrial cells in cervicovaginal smears.…”
Section: Discussionsupporting
confidence: 88%
“…[3][4][5][6][7][8][9][10][11][12][13][14][15][16][17] Little is known about the clinical significance of AGUS, favor endometrial origin (AGUS-EM). In this retrospective study, we determined the rate of a diagnosis of AGUS-EM and the incidence of clinically significant lesions in women with this cytologic diagnosis on subsequent follow-up.…”
Bethesda 2001 was developed with broad participation in the consensus process. The 2001 Bethesda System terminology reflects important advances in biological understanding of cervical neoplasia and cervical screening technology.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.